Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015', provides an overview of the Acquired (Autoimmune) Hemolytic Anemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acquired (Autoimmune) Hemolytic Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acquired (Autoimmune) Hemolytic Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Acquired (Autoimmune) Hemolytic Anemia Overview 6 Therapeutics Development 7 Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Overview 7 Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis 8 Acquired (Autoimmune) Hemolytic Anemia - Therapeutics under Development by Companies 9 Acquired (Autoimmune) Hemolytic Anemia - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Acquired (Autoimmune) Hemolytic Anemia - Products under Development by Companies 13 Acquired (Autoimmune) Hemolytic Anemia - Companies Involved in Therapeutics Development 14 Agios Pharmaceuticals, Inc. 14 Alexion Pharmaceuticals, Inc. 15 Hansa Medical AB 16 Shire Plc 17 Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AG-348 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 C1 esterase inhibitor (human) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 eculizumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Endoglycosidase of Streptococcus pyogenes - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 TNT-003 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 TNT-009 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Acquired (Autoimmune) Hemolytic Anemia - Recent Pipeline Updates 36 Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects 46 Acquired (Autoimmune) Hemolytic Anemia - Product Development Milestones 47 Featured News & Press Releases 47 Dec 08, 2014: Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency 47 Nov 06, 2014: Agios Pharmaceuticals To Present Phase 1 Data On AG-348 At The 2014 American Society Of Hematology Annual Meeting 48 Oct 06, 2014: Agios Pharmaceuticals to Provides Update on AG-348 Webcast R&D Day on October 15, 2014 49 Jun 09, 2014: Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia 50 Apr 17, 2014: Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency 50 Apr 14, 2014: True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo Efficacy of a C1s Antibody in Cold Agglutinin Disease Patient Samples 51 Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 52 Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 52 Dec 09, 2013: True North Therapeutics Presents Preclinical Results Showing Potential of TNT009 to Treat Complement-Mediated Rare Diseases 53 Jun 11, 2011: Alexion Presents Additional Data At EHA Congress Describing Long-Term Efficacy And Survival Data With Sustained Soliris Therapy 54 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H1 2015 7 Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Comparative Analysis by Unknown Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 14 Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 15 Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Hansa Medical AB, H1 2015 16 Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Shire Plc, H1 2015 17 Assessment by Monotherapy Products, H1 2015 18 Number of Products by Stage and Target, H1 2015 20 Number of Products by Stage and Mechanism of Action, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Recent Pipeline Updates, H1 2015 36 Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects, H1 2015 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.